A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis
Background & Aims Although non‐alcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC), HCC risk in non‐cirrhotic NAFLD received little attention. We aimed to develop and validate an HCC risk prediction model for non‐cirrhotic NAFLD. Methods A nationwi...
Gespeichert in:
Veröffentlicht in: | Liver international 2024-03, Vol.44 (3), p.738-748 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 748 |
---|---|
container_issue | 3 |
container_start_page | 738 |
container_title | Liver international |
container_volume | 44 |
creator | Kim, Gi‐Ae Park, Yewan Oh, Shin Ju Jung, Jooyi Han, Seungbong Chang, Hye‐Sook Park, Sung Won Kim, Tae Hyup Park, Hye Won Choe, Jaewon Kim, Jaeil Lee, Han Chu |
description | Background & Aims
Although non‐alcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC), HCC risk in non‐cirrhotic NAFLD received little attention. We aimed to develop and validate an HCC risk prediction model for non‐cirrhotic NAFLD.
Methods
A nationwide cohort of non‐cirrhotic NAFLD patients in Korea was recruited to develop a risk prediction model and validate it internally (n = 409 088). A model using a simplified point system was developed by Cox proportional hazard model. K‐fold cross‐validation assessed the accuracy, discrimination and calibration. The model was validated externally using a hospital cohort from Asan Medical Center (n = 8721).
Results
An 11‐point HCC risk prediction model for non‐cirrhotic NAFLD was developed using six independent factors of age, sex, diabetes, obesity, serum alanine aminotransferase level and gamma‐glutamyl transferase level (c‐index 0.75). The average area under receiver operating curves (AUROCs) of the model was 0.72 at 5 years and 0.75 at 10 years. In the external validation cohort, the AUROCs were 0.79 [95% confidence interval [CI], 0.59–0.95] at 5 years and 0.84 (95% CI, 0.73–0.94) at 10 years. The calibration plots showed the expected risks corresponded well with the observed risks. Risk stratification categorized patients into the low (score 0–6), moderate (7, 8) and high (9–11; estimated incidence rate >0.2%/year) risk groups.
Conclusions
A novel HCC risk prediction model for non‐cirrhotic NAFLD patients was developed and validated with fair performance. The model is expected to serve as a simple and reliable tool to assess HCC risk and assist precision screening of HCC. |
doi_str_mv | 10.1111/liv.15819 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2932708063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2932708063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2579-8464cbcf239c1fe58759d1ba21a5b7331c5bfed647107a1251d35e2287fefa913</originalsourceid><addsrcrecordid>eNp1kL1OwzAUhS0EEqUw8AaWmBjS5tpxnYxVxU-lSizAajmOrbg4cbBTqm48As_IkxAIYuMu5w7fPUf3IHQJ6QyGmTv7NgOWQ3GEJpDxPKGEwvHfTugpOotxm6ZQFAwmqFniYOML7oKurOqtb3HjK-2w8QHXupO9V9q5nZMBKxmUbX0jsW1x69vP9w_plK-9swob2fcHPMTrgCsbtYwa721f-12PlQ2h9tHGc3RipIv64len6On25nF1n2we7tar5SZRhPEiybNFpkplCC0UGM1yzooKSklAspJTCoqVRleLjEPKJRAGFWWakJwbbWQBdIquRt8u-Nedjr3Y-l1oh0hBCkp4mqcLOlDXI6WCjzFoI7pgGxkOAlLx3aYY3hE_bQ7sfGT31unD_6DYrJ_Hiy-KDXkw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2932708063</pqid></control><display><type>article</type><title>A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kim, Gi‐Ae ; Park, Yewan ; Oh, Shin Ju ; Jung, Jooyi ; Han, Seungbong ; Chang, Hye‐Sook ; Park, Sung Won ; Kim, Tae Hyup ; Park, Hye Won ; Choe, Jaewon ; Kim, Jaeil ; Lee, Han Chu</creator><creatorcontrib>Kim, Gi‐Ae ; Park, Yewan ; Oh, Shin Ju ; Jung, Jooyi ; Han, Seungbong ; Chang, Hye‐Sook ; Park, Sung Won ; Kim, Tae Hyup ; Park, Hye Won ; Choe, Jaewon ; Kim, Jaeil ; Lee, Han Chu</creatorcontrib><description>Background & Aims
Although non‐alcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC), HCC risk in non‐cirrhotic NAFLD received little attention. We aimed to develop and validate an HCC risk prediction model for non‐cirrhotic NAFLD.
Methods
A nationwide cohort of non‐cirrhotic NAFLD patients in Korea was recruited to develop a risk prediction model and validate it internally (n = 409 088). A model using a simplified point system was developed by Cox proportional hazard model. K‐fold cross‐validation assessed the accuracy, discrimination and calibration. The model was validated externally using a hospital cohort from Asan Medical Center (n = 8721).
Results
An 11‐point HCC risk prediction model for non‐cirrhotic NAFLD was developed using six independent factors of age, sex, diabetes, obesity, serum alanine aminotransferase level and gamma‐glutamyl transferase level (c‐index 0.75). The average area under receiver operating curves (AUROCs) of the model was 0.72 at 5 years and 0.75 at 10 years. In the external validation cohort, the AUROCs were 0.79 [95% confidence interval [CI], 0.59–0.95] at 5 years and 0.84 (95% CI, 0.73–0.94) at 10 years. The calibration plots showed the expected risks corresponded well with the observed risks. Risk stratification categorized patients into the low (score 0–6), moderate (7, 8) and high (9–11; estimated incidence rate >0.2%/year) risk groups.
Conclusions
A novel HCC risk prediction model for non‐cirrhotic NAFLD patients was developed and validated with fair performance. The model is expected to serve as a simple and reliable tool to assess HCC risk and assist precision screening of HCC.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.15819</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>Alanine ; Alanine transaminase ; Calibration ; Cirrhosis ; Diabetes mellitus ; Fatty liver ; Health care facilities ; Hepatocellular carcinoma ; Liver ; Liver cancer ; Liver diseases ; non‐alcoholic fatty liver disease ; Patients ; Prediction models ; Risk groups ; Statistical models</subject><ispartof>Liver international, 2024-03, Vol.44 (3), p.738-748</ispartof><rights>2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2024 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2579-8464cbcf239c1fe58759d1ba21a5b7331c5bfed647107a1251d35e2287fefa913</cites><orcidid>0000-0002-7631-4124</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.15819$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.15819$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Kim, Gi‐Ae</creatorcontrib><creatorcontrib>Park, Yewan</creatorcontrib><creatorcontrib>Oh, Shin Ju</creatorcontrib><creatorcontrib>Jung, Jooyi</creatorcontrib><creatorcontrib>Han, Seungbong</creatorcontrib><creatorcontrib>Chang, Hye‐Sook</creatorcontrib><creatorcontrib>Park, Sung Won</creatorcontrib><creatorcontrib>Kim, Tae Hyup</creatorcontrib><creatorcontrib>Park, Hye Won</creatorcontrib><creatorcontrib>Choe, Jaewon</creatorcontrib><creatorcontrib>Kim, Jaeil</creatorcontrib><creatorcontrib>Lee, Han Chu</creatorcontrib><title>A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis</title><title>Liver international</title><description>Background & Aims
Although non‐alcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC), HCC risk in non‐cirrhotic NAFLD received little attention. We aimed to develop and validate an HCC risk prediction model for non‐cirrhotic NAFLD.
Methods
A nationwide cohort of non‐cirrhotic NAFLD patients in Korea was recruited to develop a risk prediction model and validate it internally (n = 409 088). A model using a simplified point system was developed by Cox proportional hazard model. K‐fold cross‐validation assessed the accuracy, discrimination and calibration. The model was validated externally using a hospital cohort from Asan Medical Center (n = 8721).
Results
An 11‐point HCC risk prediction model for non‐cirrhotic NAFLD was developed using six independent factors of age, sex, diabetes, obesity, serum alanine aminotransferase level and gamma‐glutamyl transferase level (c‐index 0.75). The average area under receiver operating curves (AUROCs) of the model was 0.72 at 5 years and 0.75 at 10 years. In the external validation cohort, the AUROCs were 0.79 [95% confidence interval [CI], 0.59–0.95] at 5 years and 0.84 (95% CI, 0.73–0.94) at 10 years. The calibration plots showed the expected risks corresponded well with the observed risks. Risk stratification categorized patients into the low (score 0–6), moderate (7, 8) and high (9–11; estimated incidence rate >0.2%/year) risk groups.
Conclusions
A novel HCC risk prediction model for non‐cirrhotic NAFLD patients was developed and validated with fair performance. The model is expected to serve as a simple and reliable tool to assess HCC risk and assist precision screening of HCC.</description><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Calibration</subject><subject>Cirrhosis</subject><subject>Diabetes mellitus</subject><subject>Fatty liver</subject><subject>Health care facilities</subject><subject>Hepatocellular carcinoma</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>non‐alcoholic fatty liver disease</subject><subject>Patients</subject><subject>Prediction models</subject><subject>Risk groups</subject><subject>Statistical models</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kL1OwzAUhS0EEqUw8AaWmBjS5tpxnYxVxU-lSizAajmOrbg4cbBTqm48As_IkxAIYuMu5w7fPUf3IHQJ6QyGmTv7NgOWQ3GEJpDxPKGEwvHfTugpOotxm6ZQFAwmqFniYOML7oKurOqtb3HjK-2w8QHXupO9V9q5nZMBKxmUbX0jsW1x69vP9w_plK-9swob2fcHPMTrgCsbtYwa721f-12PlQ2h9tHGc3RipIv64len6On25nF1n2we7tar5SZRhPEiybNFpkplCC0UGM1yzooKSklAspJTCoqVRleLjEPKJRAGFWWakJwbbWQBdIquRt8u-Nedjr3Y-l1oh0hBCkp4mqcLOlDXI6WCjzFoI7pgGxkOAlLx3aYY3hE_bQ7sfGT31unD_6DYrJ_Hiy-KDXkw</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Kim, Gi‐Ae</creator><creator>Park, Yewan</creator><creator>Oh, Shin Ju</creator><creator>Jung, Jooyi</creator><creator>Han, Seungbong</creator><creator>Chang, Hye‐Sook</creator><creator>Park, Sung Won</creator><creator>Kim, Tae Hyup</creator><creator>Park, Hye Won</creator><creator>Choe, Jaewon</creator><creator>Kim, Jaeil</creator><creator>Lee, Han Chu</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-7631-4124</orcidid></search><sort><creationdate>202403</creationdate><title>A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis</title><author>Kim, Gi‐Ae ; Park, Yewan ; Oh, Shin Ju ; Jung, Jooyi ; Han, Seungbong ; Chang, Hye‐Sook ; Park, Sung Won ; Kim, Tae Hyup ; Park, Hye Won ; Choe, Jaewon ; Kim, Jaeil ; Lee, Han Chu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2579-8464cbcf239c1fe58759d1ba21a5b7331c5bfed647107a1251d35e2287fefa913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Calibration</topic><topic>Cirrhosis</topic><topic>Diabetes mellitus</topic><topic>Fatty liver</topic><topic>Health care facilities</topic><topic>Hepatocellular carcinoma</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>non‐alcoholic fatty liver disease</topic><topic>Patients</topic><topic>Prediction models</topic><topic>Risk groups</topic><topic>Statistical models</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Gi‐Ae</creatorcontrib><creatorcontrib>Park, Yewan</creatorcontrib><creatorcontrib>Oh, Shin Ju</creatorcontrib><creatorcontrib>Jung, Jooyi</creatorcontrib><creatorcontrib>Han, Seungbong</creatorcontrib><creatorcontrib>Chang, Hye‐Sook</creatorcontrib><creatorcontrib>Park, Sung Won</creatorcontrib><creatorcontrib>Kim, Tae Hyup</creatorcontrib><creatorcontrib>Park, Hye Won</creatorcontrib><creatorcontrib>Choe, Jaewon</creatorcontrib><creatorcontrib>Kim, Jaeil</creatorcontrib><creatorcontrib>Lee, Han Chu</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Gi‐Ae</au><au>Park, Yewan</au><au>Oh, Shin Ju</au><au>Jung, Jooyi</au><au>Han, Seungbong</au><au>Chang, Hye‐Sook</au><au>Park, Sung Won</au><au>Kim, Tae Hyup</au><au>Park, Hye Won</au><au>Choe, Jaewon</au><au>Kim, Jaeil</au><au>Lee, Han Chu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis</atitle><jtitle>Liver international</jtitle><date>2024-03</date><risdate>2024</risdate><volume>44</volume><issue>3</issue><spage>738</spage><epage>748</epage><pages>738-748</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background & Aims
Although non‐alcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC), HCC risk in non‐cirrhotic NAFLD received little attention. We aimed to develop and validate an HCC risk prediction model for non‐cirrhotic NAFLD.
Methods
A nationwide cohort of non‐cirrhotic NAFLD patients in Korea was recruited to develop a risk prediction model and validate it internally (n = 409 088). A model using a simplified point system was developed by Cox proportional hazard model. K‐fold cross‐validation assessed the accuracy, discrimination and calibration. The model was validated externally using a hospital cohort from Asan Medical Center (n = 8721).
Results
An 11‐point HCC risk prediction model for non‐cirrhotic NAFLD was developed using six independent factors of age, sex, diabetes, obesity, serum alanine aminotransferase level and gamma‐glutamyl transferase level (c‐index 0.75). The average area under receiver operating curves (AUROCs) of the model was 0.72 at 5 years and 0.75 at 10 years. In the external validation cohort, the AUROCs were 0.79 [95% confidence interval [CI], 0.59–0.95] at 5 years and 0.84 (95% CI, 0.73–0.94) at 10 years. The calibration plots showed the expected risks corresponded well with the observed risks. Risk stratification categorized patients into the low (score 0–6), moderate (7, 8) and high (9–11; estimated incidence rate >0.2%/year) risk groups.
Conclusions
A novel HCC risk prediction model for non‐cirrhotic NAFLD patients was developed and validated with fair performance. The model is expected to serve as a simple and reliable tool to assess HCC risk and assist precision screening of HCC.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/liv.15819</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7631-4124</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1478-3223 |
ispartof | Liver international, 2024-03, Vol.44 (3), p.738-748 |
issn | 1478-3223 1478-3231 |
language | eng |
recordid | cdi_proquest_journals_2932708063 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Alanine Alanine transaminase Calibration Cirrhosis Diabetes mellitus Fatty liver Health care facilities Hepatocellular carcinoma Liver Liver cancer Liver diseases non‐alcoholic fatty liver disease Patients Prediction models Risk groups Statistical models |
title | A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T20%3A30%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20risk%20prediction%20model%20for%20hepatocellular%20carcinoma%20in%20non%E2%80%90alcoholic%20fatty%20liver%20disease%20without%20cirrhosis&rft.jtitle=Liver%20international&rft.au=Kim,%20Gi%E2%80%90Ae&rft.date=2024-03&rft.volume=44&rft.issue=3&rft.spage=738&rft.epage=748&rft.pages=738-748&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.15819&rft_dat=%3Cproquest_cross%3E2932708063%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2932708063&rft_id=info:pmid/&rfr_iscdi=true |